inclusion criteria: 1. at the age of 18 or above, consent to participate in the study by voluntarily signing an icf approved by the ethics committee prior to the commencement of any study procedure; 2. subjects qualified for immunization with this product after medical history, physical examination and clinical judgment of health; 3. completion of 2 /3 doses of inactivated novel coronavirus vaccine ≥3 months; 4. the subject is able and willing to comply with the requirements of the clinical trial protocol and can complete the study follow-up for approximately 12 months; 5. armpit body temperature \< 37.3℃; 6. female non-pregnancy period (pregnancy test results are negative), non-lactation period; 7. fertile women (wocbp) subjects had taken effective contraceptive measures 1 month before enrollment; 8. wocbp subjects and male subjects have no pregnancy plans from the screening period to 6 months after the last dose of immunization, and agree to take effective contraceptive measures from the screening visit to 6 months after the last dose of immunization; 9. wocbp subjects and male subjects agree not to donate eggs (oocytes, oocytes) for assisted reproduction (wocbp subjects) or to refrain from sperm donation (male subjects) for a period of 6 months from screening visit to the last dose of immunization.

inclusion criteria: 1. at the age of 18 or above, consent to participate in the study by voluntarily signing an icf approved by the ethics committee prior to the commencement of any study procedure; 2. subjects qualified for immunization with this product after medical history, physical examination and clinical judgment of health; 3. completion of 2 /3 doses of inactivated novel coronavirus vaccine ≥3 months; 4. the subject is able and willing to comply with the requirements of the clinical trial protocol and can complete the study follow-up for approximately 12 months; 5. armpit body temperature \< 37.3℃; 6. female non-pregnancy period (pregnancy test results are negative), non-lactation period; 7. fertile women (wocbp) subjects had taken effective contraceptive measures 1 month before enrollment; 8. wocbp subjects and male subjects have no pregnancy plans from the screening period to 6 months after the last dose of immunization, and agree to take effective contraceptive measures from the screening visit to 6 months after the last dose of immunization; 9. wocbp subjects and male subjects agree not to donate eggs (oocytes, oocytes) for assisted reproduction (wocbp subjects) or to refrain from sperm donation (male subjects) for a period of 6 months from screening visit to the last dose of immunization.

inclusion criteria: at the age of 18 or above, consent to participate in the study by voluntarily signing an icf approved by the ethics committee prior to the commencement of any study procedure; subjects qualified for immunization with this product after medical history, physical examination and clinical judgment of health; completion of 2 /3 doses of inactivated novel coronavirus vaccine ≥3 months; the subject is able and willing to comply with the requirements of the clinical trial protocol and can complete the study follow-up for approximately 12 months; armpit body temperature < 37.3℃; female non-pregnancy period (pregnancy test results are negative), non-lactation period; fertile women (wocbp) subjects had taken effective contraceptive measures 1 month before enrollment; wocbp subjects and male subjects have no pregnancy plans from the screening period to 6 months after the last dose of immunization, and agree to take effective contraceptive measures from the screening visit to 6 months after the last dose of immunization; wocbp subjects and male subjects agree not to donate eggs (oocytes, oocytes) for assisted reproduction (wocbp subjects) or to refrain from sperm donation (male subjects) for a period of 6 months from screening visit to the last dose of immunization.

inclusion criteria: at the age of 18 or above, consent to participate in the study by voluntarily signing an icf approved by the ethics committee prior to the commencement of any study procedure; subjects qualified for immunization with this product after medical history, physical examination and clinical judgment of health; completion of 2 /3 doses of inactivated novel coronavirus vaccine ≥3 months; the subject is able and willing to comply with the requirements of the clinical trial protocol and can complete the study follow-up for approximately 12 months; armpit body temperature < 37.3℃; female non-pregnancy period (pregnancy test results are negative), non-lactation period; fertile women (wocbp) subjects had taken effective contraceptive measures 1 month before enrollment; wocbp subjects and male subjects have no pregnancy plans from the screening period to 6 months after the last dose of immunization, and agree to take effective contraceptive measures from the screening visit to 6 months after the last dose of immunization; wocbp subjects and male subjects agree not to donate eggs (oocytes, oocytes) for assisted reproduction (wocbp subjects) or to refrain from sperm donation (male subjects) for a period of 6 months from screening visit to the last dose of immunization.